Drugs / TQB3602
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05333276 | Jul 2022 → Dec 2023 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04275583 | May 2020 → Dec 2022 | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04275583 ↗ |
| Action | Inhibit | “This is a kind of proteasome inhibitor.” NCT04275583 ↗ |
| Route | Oral | “TQB3602 capsule administered orally” NCT04275583 ↗ |